<?xml version="1.0" encoding="UTF-8"?>
<p>During SARS and MERS epidemics, pharmacological treatment with glucocorticoids was found to result in adverse outcomes. This was the basis for World Health Organization guidelines recommend against their routine use for COVID-19 patients [
 <xref rid="CIT0067" ref-type="bibr">67</xref>, 
 <xref rid="CIT0068" ref-type="bibr">68</xref>]. However, steroids in physiological doses for adrenal insufficiency would be beneficial and improve the outcomes in these patients. The decision on hydrocortisone treatment and the appropriate dose can be guided by baseline cortisol level, and the target level expected in severely ill patients on intensive care units (see the following section).
</p>
